Curis is a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers. The Company currently has two drug candidates in development:
> CUDC-907, an orally available small molecule inhibitor of HDAC and PI3K enzymes being investigated in a Phase 2 clinical trial in patients with MYC-altered diffuse large B-cell lymphoma and in a Phase 1 trial in patients with MYC-altered solid tumors.
> CA-170, an orally-available small molecule antagonist of PD-L1 and VISTA immune checkpoints being investigated in a Phase 1 clinical trial in patients with advanced solid tumors or lymphomas.
Curis is engaged in a broad collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology. As part of this collaboration, Curis has the exclusive license to CA-170, and has also selected a second program that focuses on small molecule antagonists of PD-1 and TIM3 pathways, including compounds that target PD-L1/TIM3 immune checkpoints. Curis has also licensed the exclusive rights to orally-available small molecule inhibitors of the IRAK4 kinase, including the development candidate CA-4948 from Aurigene.
The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge® (vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. Roche and Genentech are continuing Erivedge®’s clinical development in less severe forms of BCC as well as in other diseases including idiopathic pulmonary fibrosis, or IPF, and myelofibrosis.
Sep 16, 2016
Sep 7, 2016
Aurigene to Invest in Curis at Premium Through Waiver of Certain Milestone Payments Under Collaboration Agreement
This website contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding Curis' future financial position, business strategy and plans and objectives of management for future operations. We may use such words as "believes," "expects," "anticipates," "plans," "estimates," and similar expressions to identify these forward-looking statements. There are a number of important factors that could cause Curis' actual results to differ materially from these indicated by such forward-looking statements, including those risk factors identified in the filings that Curis' makes from time to time with the SEC (click here to access SEC filings and risk factors contained herein). Curis disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.